Senti Biosciences Inc (SNTI) Stock Price, Quote & News

Company Profile

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 239 2030

Website: www.sentibio.com

Address:

2 Corporate Drive, First Floor, South San Francisco, United States

LegacyX1983 Jan. 13 at 2:39 PM

$SNTI $XAIR $AHMA $ATON These are my holds. Big moves coming. I still think SNTI will explode today. It’s only $1 with a $13 price target. Huge pipeline. Let’s get rich!!

1 · Reply

haydenjc Jan. 13 at 12:50 PM

$SNTI today the day we go under a dollar?? By Friday, not looking good

0 · Reply

Samuelstark Jan. 13 at 3:02 AM

$SNTI 10am CST tomorrow. bullish

0 · Reply

LegacyX1983 Jan. 12 at 10:03 PM

$SNTI $EVTV $PLTR These are my holds over night. Expecting big moves. Snti is only $1 with a $13 price target. Let’s get rich.

2 · Reply

JamesMBMM Jan. 12 at 9:00 PM

$SNTI Coming up

0 · Reply

haydenjc Jan. 12 at 3:15 PM

$SNTI out, bbl under 1

0 · Reply

haydenjc Jan. 12 at 1:28 PM

$SNTI of course. Trying to push under a dollar still.

0 · Reply

haydenjc Jan. 12 at 12:52 PM

$SNTI this price action is a bit ridiculous. Let’s get this moving slowly up to at least 3+ where we should be sitting. Smdh

0 · Reply

SPYmyQQQ Jan. 12 at 11:03 AM

🚀 New Signal ✅ 💊 $SNTI 🗓️ Jan 12, 2026 💵 Entry: $1.15 🎯 Target (Opt.): $1.35 (+17.39%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

lowriskdailycompounder Jan. 11 at 10:31 AM

$SNTI Biotech Showcase / JPM-week panel participation (headline catalyst). Biotech names often get retail chatter; SNTI shows in Reddit searches. Pre-revenue biotech (Sales shown as 0 on Finviz), so “undervalued” is hard—moves on trial/news. Strongest verified squeeze setup in your list: Short Float 24.50%, Float 6.79M, Short Interest 1.66M.

0 · Reply

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Jan 9, 2026, 8:55 AM EST - 5 days ago

Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

Dec 18, 2025, 5:30 PM EST - 26 days ago

Senti Biosciences Announces New Employment Inducement Grants

$Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia$

Dec 9, 2025, 7:00 AM EST - 5 weeks ago

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

$Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile$

Dec 9, 2025, 7:00 AM EST - 5 weeks ago

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

Dec 4, 2025, 8:45 AM EST - 5 weeks ago

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET

Nov 13, 2025, 4:30 PM EST - 2 months ago

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Nov 3, 2025, 9:05 AM EST - 2 months ago

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 16, 2025, 9:05 AM EDT - 3 months ago

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

Oct 6, 2025, 9:05 AM EDT - 3 months ago

Senti Bio to Present at BioJapan

Sep 18, 2025, 9:15 AM EDT - 4 months ago

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Sep 2, 2025, 9:05 AM EDT - 4 months ago

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 9:15 AM EDT - 5 months ago

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 12, 2025, 9:15 AM EDT - 5 months ago

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Aug 7, 2025, 8:05 AM EDT - 5 months ago

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

$Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia$

Aug 5, 2025, 8:30 AM EDT - 5 months ago

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Jul 22, 2025, 8:45 AM EDT - 6 months ago

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 21, 2025, 8:55 AM EDT - 6 months ago

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

Jul 18, 2025, 8:55 AM EDT - 6 months ago

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

Jun 30, 2025, 9:15 AM EDT - 7 months ago

Senti Bio Participates in Nasdaq Amplify Spotlight Series

Jun 24, 2025, 8:45 AM EDT - 7 months ago

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

Jun 18, 2025, 7:00 AM EDT - 7 months ago

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Jun 6, 2025, 9:05 AM EDT - 7 months ago

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

May 30, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation

May 29, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

May 28, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

May 27, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 8 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

May 22, 2025, 4:05 PM EDT - 8 months ago

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

May 22, 2025, 8:30 AM EDT - 8 months ago

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 21, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

May 20, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out

May 20, 2025, 5:28 AM EDT - 8 months ago

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

May 19, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Reach Out

May 18, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Connect

May 16, 2025, 2:00 PM EDT - 8 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 8, 2025, 8:35 AM EDT - 8 months ago

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

May 6, 2025, 4:35 PM EDT - 9 months ago

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

LegacyX1983 Jan. 13 at 2:39 PM

$SNTI $XAIR $AHMA $ATON These are my holds. Big moves coming. I still think SNTI will explode today. It’s only $1 with a $13 price target. Huge pipeline. Let’s get rich!!

1 · Reply

haydenjc Jan. 13 at 12:50 PM

$SNTI today the day we go under a dollar?? By Friday, not looking good

0 · Reply

Samuelstark Jan. 13 at 3:02 AM

$SNTI 10am CST tomorrow. bullish

0 · Reply

LegacyX1983 Jan. 12 at 10:03 PM

$SNTI $EVTV $PLTR These are my holds over night. Expecting big moves. Snti is only $1 with a $13 price target. Let’s get rich.

2 · Reply

JamesMBMM Jan. 12 at 9:00 PM

$SNTI Coming up

0 · Reply

haydenjc Jan. 12 at 3:15 PM

$SNTI out, bbl under 1

0 · Reply

haydenjc Jan. 12 at 1:28 PM

$SNTI of course. Trying to push under a dollar still.

0 · Reply

haydenjc Jan. 12 at 12:52 PM

$SNTI this price action is a bit ridiculous. Let’s get this moving slowly up to at least 3+ where we should be sitting. Smdh

0 · Reply

SPYmyQQQ Jan. 12 at 11:03 AM

🚀 New Signal ✅ 💊 $SNTI 🗓️ Jan 12, 2026 💵 Entry: $1.15 🎯 Target (Opt.): $1.35 (+17.39%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

lowriskdailycompounder Jan. 11 at 10:31 AM

0 · Reply

LegacyX1983 Jan. 10 at 12:06 AM

$SNTI

0 · Reply

LegacyX1983 Jan. 8 at 11:49 PM

$SNTI $CGTL $FLYX Let’s go. These are my holds over night. Snti is current $1 with a $13 price target. Let’s go!!!

0 · Reply

haydenjc Jan. 8 at 9:20 PM

$GPUS mad gains made here in the future has a safe place at $SNTI for more growth. Just something to look into while we wait for a dollar or 2 or 4.

0 · Reply

Samuelstark Jan. 8 at 3:42 AM

$SNTI I have a good feeling about the coming weeks. More vibes than anything.

0 · Reply

Biggame417 Jan. 7 at 2:20 PM

$SNTI

0 · Reply

haydenjc Jan. 7 at 1:06 PM

$SNTI this bitch is a waste of time with this 10-13 bullshit. Doesn’t mean shit when they continue to drop and before you know it, some bullshit and we get fucked. Always happens Under a dollar by Friday is my guess

0 · Reply

rangervs Jan. 6 at 9:16 PM

$SNTI they should send this ! Wasn’t there a $12+ projection

0 · Reply

LegacyX1983 Jan. 5 at 8:42 PM

$SNTI $PLTR $TSLA I’m expecting big moves from my holds. Especially my penny stock snti. Let’s go everyone! Let’s get rich!

0 · Reply

crainiac Jan. 5 at 12:04 PM

$SNTI SNTI files joint World Patent Application with Bluerock Therapeutics https://www.freepatentsonline.com/WO2026006316A2.html

0 · Reply

crainiac Jan. 5 at 12:02 PM

$SNTI SNTI awarded new Japanese patent https://www.freepatentsonline.com/JP7792335B2.html

0 · Reply

UgoGreg Jan. 4 at 5:27 PM

$SNTI https://youtu.be/pXFO9_cJJUM

0 · Reply

UgoGreg Jan. 4 at 4:18 PM

$SNTI https://youtu.be/ygBN8MilTyc

0 · Reply

Market Cap	29.45M
Revenue (ttm)	0.00
Net Income (ttm)	-52.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	274,100
Avg Vol	1,917,228
Day's Range	N/A - N/A
Shares Out	26.29M
Stochastic %K	14%
Beta	2.13
Analysts	Strong Sell
Price Target	$10.33